SCHEMBL30737782

SCHEMBL30737782

CNC(=O)c1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 20/20 1.00
FGFR2 P21802 20/20 1.00
FGFR3 P22607 20/20 1.00
FGFR4 P22455 19/20 1.00
KDR P35968 18/20 1.00
FLT3 P36888 9/20 1.00
ADORA3 P0DMS8 1/20 0.81
CHRM1 P11229 1/20 0.81
ADRA2C P18825 1/20 0.81
SLC6A2 P23975 1/20 0.81
SLC6A4 P31645 1/20 0.81
DRD3 P35462 1/20 0.81
OPRD1 P41143 1/20 0.81
ETV6 P41212 1/20 0.81
HTR2B P41595 1/20 0.81
SLC6A3 Q01959 1/20 0.81
PDE4D Q08499 1/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12179158 1.00 FGFR1 (1.00) FGFR1FGFR2FGFR3FGFR4KDR
SCHEMBL12178503 0.92 FGFR1 (1.00) FGFR1FGFR2FGFR3FGFR4KDR
SCHEMBL30737884 0.92 FGFR1 (1.00) FGFR1FGFR2FGFR3FGFR4KDR
SCHEMBL18176332 0.90 FGFR3 (0.87) FGFR1FGFR2FGFR3FGFR4KDR
Erdafitinib SCHEMBL2583760 0.90 FGFR1 (1.00) FGFR1FGFR2FGFR3FGFR4KDR
Erdafitinib SCHEMBL29359988 0.90 FGFR1 (1.00) FGFR1FGFR2FGFR3FGFR4KDR
SCHEMBL12178781 0.90 FGFR1 (1.00) FGFR1FGFR2FGFR3FGFR4KDR
SCHEMBL30737905 0.90 FGFR1 (1.00) FGFR1FGFR2FGFR3FGFR4KDR
SCHEMBL12178776 0.89 FGFR1 (1.00) FGFR1FGFR2FGFR3FGFR4KDR
SCHEMBL30737930 0.89 FGFR1 (1.00) FGFR1FGFR2FGFR3FGFR4KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023240271-A1 USE OF VEGFR2 AND FGFR1 INHIBITORS IN THERAPY FOUNTAIN THERAPEUTICS INC. (US) 2023-12-14 WO claimed
WO-2023240271-A1 USE OF VEGFR2 AND FGFR1 INHIBITORS IN THERAPY FOUNTAIN THERAPEUTICS INC. (US) 2023-12-14 WO disclosed